medRxiv · 2021 · 90 citations · 2 references
Life SciencesImmunologyInfectious DiseasesClinical ImmunologyMolecular VirologyVaccinologyAntiviral ImmunityVaccinationVaccine EffectivenessVaccine-preventable DiseasesNeutralizationNeutralization TheorySars-cov-2 InfectionSevere Acute Respiratory Syndrome
Abstract Recently, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant B.1.1.529 (Omicron) has been described. Here, we analyze titers of neutralizing antibodies of sera from convalescent or vaccinated individuals against the new B.1.1.529 variant and compared them with titers against other Variants of Concern (B.1.1.7, B.1.351, B.1617.2) using replication competent SARS-CoV-2 variants. We found that sera from vaccinated individuals neutralized the B.1.1.529 variant to a much lesser extent than any other variant analyzed. Neutralization capacity against B.1.1.529 was maintained best against sera from super immune individuals (infected and vaccinated or vaccinated and infected).
2
Comparison of Four SARS-CoV-2 Neutralization Assays
Lydia Riepler, Annika Rössler, Albert Falch et al. · Vaccines · 2020 · 134 citations · Full text